Which medication is more likely to precipitate supraventricular tachycardia, duloxetine (Cymbalta) or escitalopram (Lexapro)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lexapro (escitalopram) is more likely to contribute to SVT than Cymbalta (duloxetine)

Based on the most recent and highest quality pharmacovigilance data, escitalopram demonstrates a stronger signal for supraventricular tachycardia risk, while duloxetine (an SNRI) shows no significant association with arrhythmic events including SVT.

Evidence Analysis

Duloxetine (Cymbalta) - Lower SVT Risk

The 2025 FAERS database analysis 1 specifically examined arrhythmic events across antidepressants and found that venlafaxine and duloxetine (both SNRIs) did not show any pharmacovigilance signal for any arrhythmia and demonstrated lower risks compared to SSRIs. This is the most recent, large-scale comparative data available.

Additionally, a 2024 OpenVigil database analysis 2 mining for drugs associated with SVT risk identified venlafaxine (another SNRI) as a culprit, but duloxetine was not among the six drugs most likely to cause SVT. The drugs identified were: salbutamol, paroxetine, formoterol, paclitaxel, venlafaxine, and theophylline.

While duloxetine does cause modest increases in heart rate (2.22 beats/min) and diastolic blood pressure (0.82 mmHg) 3, and case reports of tachycardia exist 4, these represent sinus tachycardia rather than SVT specifically.

Escitalopram (Lexapro) - Higher SVT Risk

The FDA label 5 documents cardiac arrhythmias in post-marketing surveillance, specifically listing: atrial fibrillation, tachycardia, ventricular arrhythmia, and ventricular tachycardia as reported adverse events. While the label doesn't explicitly list "SVT," atrial fibrillation is a form of supraventricular arrhythmia.

The 2025 FAERS analysis 1 found pharmacovigilance signals for escitalopram across multiple arrhythmias:

  • QT prolongation/TdP (ROR = 1.72)
  • Atrial fibrillation (ROR = 1.34)
  • Ventricular arrhythmia (ROR = 1.51)

The 2014 European Heart Journal guideline 6 notes that SSRIs as a class significantly increased cardiac arrest risk (OR 1.21), though SNRIs showed no association.

Clinical Implications

When prescribing for patients with arrhythmia concerns or risk factors:

  • Choose duloxetine over escitalopram if both are therapeutically appropriate
  • Duloxetine's cardiovascular effects are primarily limited to modest increases in heart rate and blood pressure, not arrhythmogenesis
  • Escitalopram carries documented risk of atrial fibrillation and other arrhythmias in post-marketing data

Common pitfall to avoid: Assuming all antidepressants carry equal cardiac risk. The evidence clearly distinguishes SNRIs (particularly duloxetine) as having lower arrhythmic potential compared to SSRIs like escitalopram.

If escitalopram must be used: Obtain baseline ECG in patients with cardiac risk factors, monitor for palpitations, and consider lower doses (10 mg vs 20 mg) as the FDA label shows dose-dependent effects 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.